Cofactors

Worldwide Industry for Methylcobalamin to 2025 - Impact of COVID-19

Retrieved on: 
Thursday, November 5, 2020
Chemistry, Physical sciences, B vitamins, Cofactors, Chemical elements, Vitamin B12, Methylcobalamin, Cobalt, Marketplace, Economy of China

This report is a professional and in-depth study on the current state of the global Methylcobalamin market with a focus on the Chinese market.

Key Points: 
  • This report is a professional and in-depth study on the current state of the global Methylcobalamin market with a focus on the Chinese market.
  • It is a valuable source of guidance and direction for companies and individuals interested in Methylcobalamin industry.
  • The global Methylcobalamin market is further divided by company, by country, and by application/type for the competitive landscape analysis.
  • Overall, the report provides an in-depth insight of 2015-2025 global and Chinese Methylcobalamin market covering all important parameters.

Methylcobalamin Market Insights (2020 to 2025) - Analysis and Forecast for the Global and Chinese Markets - ResearchAndMarkets.com

Retrieved on: 
Monday, November 2, 2020
Health, Pharmaceutical, Chemistry, Physical sciences, Natural sciences, B vitamins, Cofactors, Vitamin B12, Methylcobalamin, Cobalt

The report explores Global and Chinese major players in Methylcobalamin market.

Key Points: 
  • The report explores Global and Chinese major players in Methylcobalamin market.
  • The report depicts the global and Chinese total Methylcobalamin market including: capacity, production, production value, cost/profit, supply/demand and Chinese import/export, by statistical analysis.
  • The global Methylcobalamin market is further divided by company, by country, and by application/type for the competitive landscape analysis.
  • Overall, the report provides an in-depth insight of 2015-2025 global and Chinese Methylcobalamin market covering all important parameters.

Octapharma announces FDA approval of updated NUWIQ® Prescribing Information to include immunogenicity data in previously untreated patients

Retrieved on: 
Monday, October 19, 2020
FDA, Pharmaceutical, Genetics, Health, Blood, Branches of biology, Haemophilia, Recombinant proteins, Coagulation system, Proteins, Cofactors, Factor VIII, Octapharma, Haemophilia A, Recombinant factor VIIa, Acquired haemophilia, Haemophilia A, Nuwiq®, Octapharma

Octapharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved an updated Prescribing Information (PI) for NUWIQ, Octapharmas human cell line-derived recombinant factor VIII (FVIII).

Key Points: 
  • Octapharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved an updated Prescribing Information (PI) for NUWIQ, Octapharmas human cell line-derived recombinant factor VIII (FVIII).
  • The updated PI includes immunogenicity data from the NuProtect study in previously untreated patients (PUPs).
  • FVIII inhibitor development is the most serious treatment complication in previously untreated patients (PUPs) with severe haemophilia A.
  • The updated NUWIQ PI includes data from the NuProtect study, which was the largest prospective study of a single FVIII product in true PUPs.

Outlook on the Worldwide Heme Industry to 2025 - Featuring Sichuan Deebio & Impossible Foods

Retrieved on: 
Tuesday, June 23, 2020
Porphyrins, Biomolecules, Cofactors, Heme

This report is a professional and in-depth study on the current state of the global Heme market with a focus on the Chinese market.

Key Points: 
  • This report is a professional and in-depth study on the current state of the global Heme market with a focus on the Chinese market.
  • Key points of Heme Market Report:
    The report provides a basic overview of Heme industry including: definition, applications and manufacturing technology.
  • The global Heme market is further divided by company, by country, and by application/type for the competitive landscape analysis.
  • Overall, the report provides an in-depth insight of the 2015-2025 global and Chinese Heme market covering all important parameters.

Heme Market Insights (2020 to 2025) - Analysis and Forecasts for the Global and Chinese Markets - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 16, 2020
Retail, Chemicals, Plastics, Manufacturing, Food, Beverage, Porphyrins, Biomolecules, Cofactors, Heme

The report explores Global and Chinese major players in Heme market.

Key Points: 
  • The report explores Global and Chinese major players in Heme market.
  • The report depicts the global and Chinese total Heme market including: capacity, production, production value, cost/profit, supply/demand and Chinese import/export, by statistical analysis.
  • The global Heme market is further divided by company, by country, and by application/type for the competitive landscape analysis.
  • Overall, the report provides an in-depth insight of the 2015-2025 global and Chinese Heme market covering all important parameters.

RAPID DOSE THERAPEUTICS DONATES QUICKSTRIP™ VITAMIN B12 NUTRACEUTICAL PRODUCT TO COMMUNITY

Retrieved on: 
Thursday, April 2, 2020
Branches of biology, B vitamins, Cofactors, Vitamin B12, Health, Vitamin, B12

BURLINGTON, Ontario, April 02, 2020 (GLOBE NEWSWIRE) -- Rapid Dose Therapeutics Corp. (CSE: DOSE) (RDT or the Corporation) in response to the COVID pandemic, recently made a donation to the Burlington Foodbank contributing over 16,000 QuickStrip Vitamin B12 product to distribute to those in need in the community, to support overall general health in these unprecedented times.

Key Points: 
  • BURLINGTON, Ontario, April 02, 2020 (GLOBE NEWSWIRE) -- Rapid Dose Therapeutics Corp. (CSE: DOSE) (RDT or the Corporation) in response to the COVID pandemic, recently made a donation to the Burlington Foodbank contributing over 16,000 QuickStrip Vitamin B12 product to distribute to those in need in the community, to support overall general health in these unprecedented times.
  • Vitamin B12 can help in red blood cell formation, cell metabolism, nerve function and maintaining healthy nervous and cardiovascular systems.
  • Rapid Dose Therapeutics Corp. is a publicly traded Canadian life sciences company that provides innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives.
  • RDT is focused and committed to clinical research and product development for the healthcare manufacturing industry, including nutraceutical, pharmaceutical and cannabis industries.

New AACC Guidance Document Outlines How Healthcare Professionals Can Prevent the Widespread Supplement Biotin From Interfering With Medical Tests

Retrieved on: 
Monday, January 13, 2020
Branches of biology, Health, Organic compounds, Biotin, Cofactors, Ureas, Vitamin, Immunoassay, Multivitamin, Dietary supplement

WASHINGTON, Jan. 13, 2020 /PRNewswire/ --Biotin's upsurge in popularity has led to a parallel rise in incidents of this health supplement interfering with critical medical tests.

Key Points: 
  • WASHINGTON, Jan. 13, 2020 /PRNewswire/ --Biotin's upsurge in popularity has led to a parallel rise in incidents of this health supplement interfering with critical medical tests.
  • A new guidance document from AACC urges clinicians and laboratory experts to collaborate to prevent this potentially harmful test interference, and to ensure that patients taking biotin receive high quality care.
  • At least a fifth of Americans take biotin, either as a beauty supplement, as part of an over-the-counter multivitamin, or as a treatment for medical conditions such as multiple sclerosis.
  • If a patient takes biotin supplements, the biotin in his or her blood sample competes with the biotin used in immunoassays and can falsely increase or decrease the results of these tests.

Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment

Retrieved on: 
Saturday, December 7, 2019
Stem cells, Biotechnology, FDA, Health, Pharmaceutical, Oncology, Research, Hospitals, Genetics, Science, Clinical trials, Branches of biology, Natural sciences, Recombinant proteins, Coagulation system, Chemistry, Cofactors, Factor VIII, ELISA, Assay, the Alta study, SB-525 Gene Therapy, Sangamo Therapeutics

The data showed that SB-525 was generally well tolerated and demonstrated sustained increased Factor VIII (FVIII) levels following treatment with SB-525 through to 44 weeks, the extent of follow-up for the longest treated patient in the 3e13 vg/kg dose cohort.

Key Points: 
  • The data showed that SB-525 was generally well tolerated and demonstrated sustained increased Factor VIII (FVIII) levels following treatment with SB-525 through to 44 weeks, the extent of follow-up for the longest treated patient in the 3e13 vg/kg dose cohort.
  • An analysis of plasma FVIII antigen was assessed by ELISA and demonstrated antigen concentrations consistent with the FVIII activity measured by the chromogenic assay.
  • The lower-dose cohorts indicate durable FVIII activity with up to 52 weeks of follow-up.
  • In the 3e13 vg/kg dose cohort, patients achieved normal range FVIII activity within 5-7 weeks of treatment with SB-525.

BridgeBio Pharma’s Origin Biosciences Initiates Rolling Submission of New Drug Application with the U.S. FDA for BBP-870 for the Treatment of MoCD Type A

Retrieved on: 
Tuesday, December 3, 2019
Chemistry, Physical sciences, Organophosphates, Chemical elements, Molybdenum cofactor deficiency, Cofactors, Pteridines, Cyclic pyranopterin monophosphate, CPMP, Pterin, Molybdenum, MOCS1

Currently, there are no approved therapies that alter the course of MoCD Type A, which results in severe and irreversible neurological injury.

Key Points: 
  • Currently, there are no approved therapies that alter the course of MoCD Type A, which results in severe and irreversible neurological injury.
  • As we begin our first rolling new drug application with the FDA, we are taking a significant step forward for patients by targeting MoCD Type A at its source through the provision of the monophosphate cPMP.
  • Together with patients and physicians, the company aims to bring a safe, effective treatment for MoCD Type A to market as quickly as possible.
  • Efficacy and safety of cyclic pyranopterin monophosphate substitution in severe molybdenum cofactor deficiency type A: a prospective cohort study.

Parabel Announces Natural Plant Source of Vitamin B12 in Water Lentils and LENTEIN® Plant Protein

Retrieved on: 
Monday, November 18, 2019
Nutrients, Nutrition, Dietary Supplements, Vitamin B12, Cofactors, RTT, Fabeae, Lentil, Vitamin, Methylcobalamin, B vitamins, Hydroxocobalamin

VERO BEACH, Fla., Nov. 18, 2019 /PRNewswire/ -- Parabel USA Inc , producer of plant protein ingredients, today announced the discovery of a natural plant-based source of Vitamin B12 in its water lentil crop.

Key Points: 
  • VERO BEACH, Fla., Nov. 18, 2019 /PRNewswire/ -- Parabel USA Inc , producer of plant protein ingredients, today announced the discovery of a natural plant-based source of Vitamin B12 in its water lentil crop.
  • Independent third-party laboratory testing has confirmed that Parabel's water lentil crop and the ingredient LENTEIN plant protein contain the natural bioactive forms of Vitamin B 12 adenosylcobalamin, methycobalamin, and hydroxocobalamin.
  • Along with partners, we will begin conducting bioavailability studies to determine the effectiveness of water lentils as a natural, plant-based solution to address vitamin B12 deficiencies."
  • Parabel USA Inc., based in Vero Beach, Florida, grows and processes water lentils into LENTEIN plant protein.